Detalles de la búsqueda
1.
Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition.
Cell
; 147(6): 1384-96, 2011 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-22153080
2.
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Br J Cancer
; 130(3): 425-433, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38097739
3.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38412736
4.
Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.
Support Care Cancer
; 32(5): 292, 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38632132
5.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Br J Cancer
; 129(5): 797-810, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37474720
6.
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol
; 173: 130-137, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148580
7.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol
; 174: 213-223, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37229879
8.
Profiling the immune landscape in mucinous ovarian carcinoma.
Gynecol Oncol
; 168: 23-31, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36368129
9.
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
J Natl Compr Canc Netw
; 21(2): 125-132.e3, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36791763
10.
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
Can J Surg
; 66(3): E310-E320, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37369443
11.
Vaccine Effectiveness during Outbreak of COVID-19 Alpha (B.1.1.7) Variant in Men's Correctional Facility, United States.
Emerg Infect Dis
; 28(7): 1313-1320, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35731137
12.
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
Cancer
; 128(7): 1449-1457, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34985773
13.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med
; 381(25): 2403-2415, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562800
14.
Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.
J Transl Med
; 20(1): 564, 2022 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36474270
15.
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Gynecol Oncol
; 164(2): 437-445, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34955238
16.
Germline BRCA variants, lifestyle and ovarian cancer survival.
Gynecol Oncol
; 165(3): 437-445, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35400525
17.
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol
; 164(2): 278-287, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34930617
18.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol
; 165(1): 40-48, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35115180
19.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Gynecol Oncol
; 166(3): 410-416, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835612
20.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35718565